Advertisement

Picture Berlin Partner HealthCapital Bionnale 2019 Germany May 650x80px
Document › Details

OSE Immunotherapeutics S.A.. (9/7/17). "Press Release: OSE Immunotherapeutics Reports on First-Half 2017 Financial Results and Provides Update on Clinical Advances of its Product Portfolio". Nantes.

Organisations Organisation OSE Immunotherapeutics S.A.
  Today OSE Pharma S.A.
  Group OSE Immunotherapeutics (Group)
  Organisation 2 Janssen Biotech Inc. (JBI)
  Group Johnson & Johnson (JnJ) (Group)
Products Product Tedopi® cancer immunotherapy
  Product 2 FR104 MAb fragment (Effimmune)
Index term Index term Servier–OSE Immunotherapeutics: therapeutic antibody, 201612– license option ww excl up to €272m for Effi-7 immunomodulatory antibody to Servier
Persons Person Costantini, Dominique (OSE Pharma 201504 CEO + Co-founder + former CEO + Co-founder of BioAlliance Pharma in 1997)
  Person 2 de Weese, David (Paul Capital 201504 Director + Board Member of OSE Pharma)
     


   
Record changed: 2017-09-18

Advertisement

Picture Kentro Design Corporate and Web Design Berlin 650x65px

More documents for OSE Immunotherapeutics (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

Picture ConsulTech GmbH Berlin Grant Application and Coordination 650x80px




» top